(Q36389193)

English

Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. (English)

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Larry Norton

12

0 references

13

object named as

Hyman Muss

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Gretchen G Kimmick

11

object named as

Gretchen Kimmick

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

6

object named as

Ruth O'Regan

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

5

object named as

Edith A Perez

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Constance T Cirrincione

2

object named as

Constance T Cirrincione

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Lawrence N Shulman

1

object named as

Lawrence N Shulman

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Clifford A Hudis

15

object named as

Clifford Hudis

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

14

object named as

Eric P Winer

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

3

object named as

Donald A Berry

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Heather P Becker

4

object named as

Heather P Becker

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Silvana Martino

7

object named as

Silvana Martino

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

9

object named as

Erica Mayer

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

author name string

James N Atkins

8

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Charles J Schneider

10

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

language of work or name

0 references

publication date

23 July 2012

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

30

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

33

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

4071-4076

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494835

30 September 2017

Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494835

30 September 2017

Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAK

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494835

30 September 2017

Adjuvant docetaxel for high-risk, node-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494835

28 June 2018

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494835

21 September 2018

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494835

21 September 2018

Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol I

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494835

21 September 2018

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494835

21 September 2018

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494835

21 September 2018

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3494835

5 December 2018

Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results

1 reference

https://pubmed.ncbi.nlm.nih.gov/22826271

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system

1 reference

https://pubmed.ncbi.nlm.nih.gov/22826271

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

1 reference

https://pubmed.ncbi.nlm.nih.gov/22826271

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2011.40.6405

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36389193&oldid=1872228233"